Rise of Artificial Intelligence Technology Gives Healthcare More Room for ImaginationAI+
biomedicalWhen the two "wind mouths" meet head-on
What will happen?
In the field of biomedicine
There's a "3 laws of 10" about new drug development.
i.e., it takes an average of 10 years and costs $1 billion
And the success rate is only 10%.
Why is it so difficult? Taking cancer as an example, if the tumor is a lock, the target is the eye of the lock, and the drug is the key, in order to find the most suitable key, a lot of energy and financial resources need to be spent on screening.
In Nanjing Biomedical Valley
Already a group of entrepreneurs, scientists
Through artificial intelligence technology
To develop innovative drugs and innovative medical devices
Cambrian Wisdom (Nanjing) Biomedical Technology Co.
Unlike traditional pharmaceutical R&D teams, who all wear white coats to do experiments, some people in the R&D center of Cambu Zhiyuan (Nanjing) Biomedical Technology Co., Ltd. are analyzing the image data on the computer screen. The team includes scientists from different fields such as brain science, photovoltaic conversion, bioinformatics acquisition, drug development, etc., and all of them are cooperating.Utilizing the powerful image processing capabilities of artificial intelligence to find effective compounds, develops drugs for neurological disorders such as depression, schizophrenia, and Alzheimer's disease.
Currently, Cambrian Wisdom has developed a research and development platform based on brain-like tissue chip-assisted AI parsing, with completely independent intellectual property rights. "The leading point of the platform isVisualizing the workings of the brain and the effects of drugs on brain functioning, which is due to the advances in big data, big AI models and GPU technology." Nan Wang, director of data analysis at Cambium Wisdom, said.
Nanjing Chengshi Biomedical Technology Co.
mRNA vaccine is the most advanced technology system in the vaccine industry, Nanjing Chengshi Biomedical Technology Co.AI-driven development of mRNA vaccine products. Currently the company's product system is divided into two main categories, on the one hand, the development of therapeutic vaccines against human tumors, and on the other hand, the development of prophylactic vaccines for use in economic animals.
"In the past, mRNA vaccines were designed mainly by manual experiments to screen and design antigens.We use artificial intelligence to calculate the way to go about screening antigens, which is more than 10 times more efficient."Fei Caiyi, vice president of Chengshi Biologicals, introduced that the company has set up an intelligent information team spanning a number of specialized disciplines, which has greatly accelerated the entire antigen and vaccine design tempo by cooperating with the biology team and the clinical immunology team.
At present, Chengshi Bio has established a completely independent and autonomous technology system, such as artificial intelligence antigen design system and mRNA design system, based on which multiple R&D pipelines of mRNA therapeutic vaccines for acute leukemia, liver cancer, cerebral glioma, breast cancer and osteosarcoma are being accelerated.
"In the field of economic animals, our R&D pipeline is advancing very fast, and a number of products have been finalized and are expected to be available next year." Fei Caiyi said that mRNA vaccines are likely to enable China's veterinary vaccines to realize "lane-changing overtaking".
Topmicro Facsimile Data Technology (Nanjing) Co.
The heart is one of the most important organs in the human body, it consists of the left atrium, left ventricle, right atrium and right ventricle, and the key tissue connecting these two chambers is the heart valve. Once the heart valve problems, the most advanced treatment is through minimally invasive surgery for artificial heart valve implantation. In the Pharmaceutical Valley Park, Topmicro Facsimile Heart Data Technology (Nanjing) Co.Artificial Intelligence Valve Surgery Planning System (CVPILOT) to "navigate" heart valve surgery.
"During the interventional procedure, the artificial heart valve has to be placed in the right position of the heart through the delivery system." Wang Yuan, deputy general manager of Topmicro Facsimile Heart Data Technology (Nanjing) Co., Ltd. introduced that judging the "appropriate location" is a great test for doctors, and with CVPILOT, doctors only need to import the patient's CT image into the system, and then they can see the patient's 3D cardiac structure map, and obtain fully automated auxiliary parameters, which can more intuitively, quickly and accurately select the area for placing the artificial heart valve. It is able to select the area for placing the prosthetic heart valve more intuitively, quickly and accurately.
